Moreover, PSMA-PET is used in advanced stages of castration resistant prostate cancer to assess PSMA expression as a prerequisite for eligibility of radioligand therapy or to monitor the disease burden and decide on treatment intensification [4–7]. The gene discussed is FOLH1; the disease is prostate carcinoma.